AR081159A1 - Anticuerpos humanizados 12g4 mutados y sus fragmentos dirigidos contra el receptor humano de la hormona anti-mulleriana de tipo ii - Google Patents

Anticuerpos humanizados 12g4 mutados y sus fragmentos dirigidos contra el receptor humano de la hormona anti-mulleriana de tipo ii

Info

Publication number
AR081159A1
AR081159A1 ARP110101115A ARP110101115A AR081159A1 AR 081159 A1 AR081159 A1 AR 081159A1 AR P110101115 A ARP110101115 A AR P110101115A AR P110101115 A ARP110101115 A AR P110101115A AR 081159 A1 AR081159 A1 AR 081159A1
Authority
AR
Argentina
Prior art keywords
seq
represented
amino acid
acid sequence
mullerian hormone
Prior art date
Application number
ARP110101115A
Other languages
English (en)
Inventor
Christian Behrens
Original Assignee
Univ Montpellier I
Ct Nat De Lutte Contre Le Cancer
Inst Nat Sante Rech Med
Lfb Biotechnologies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Montpellier I, Ct Nat De Lutte Contre Le Cancer, Inst Nat Sante Rech Med, Lfb Biotechnologies filed Critical Univ Montpellier I
Publication of AR081159A1 publication Critical patent/AR081159A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)

Abstract

Anticuerpos humanizados 12G4 mutados, y sus fragmentos, dirigidos contra el receptor de la hormona anti-mulleriana de tipo II. Acido nucleico, vector, célula hospedante y composición farmacéutica que lo contiene. Reivindicación 1: Anticuerpo monoclonal humanizado 12G4 que comprende o está constituido por: a) una cadena ligera que comprende o está constituida por: una región variable en donde la secuencia de aminoácidos está representada por SEQ ID Ns 2 ó SEQ ID Ns 4, y una región constante en donde la secuencia de aminoácidos está representada por SEQ ID Ns 6 o por una secuencia que presenta al menos 80% de homología con la SEQ ID Ns 6; b) una cadena pesada que comprende o está constituida por: una región variable en donde la secuencia de aminoácidos está representada por SEQ ID Ns 8, ó SEQ ID Ns 10, y una región constante en donde la secuencia de aminoácidos está representada por SEQ ID Ns 12 o por una secuencia que presenta al menos 80% de homología con la SEQ ID Ns 12; el cual anticuerpo monoclonal humanizado 12G4 está mutado, comprende al menos una mutación en la cadena ligera y/o pesada, y presenta un KD para el receptor de tipo II de la hormona anti-mulleriana humana (AMHRII) al menos igual a la del anticuerpo monoclonal quimérico 12G4 que comprende o está constituido por: una región variable en donde la secuencia de aminoácidos está representada por SEQ ID Ns 14, y una región constante en donde la secuencia de aminoácidos está representada por SEQ ID Ns 6, b) una cadena pesada constituida por: una región variable en donde la secuencia de aminoácidos está representada por SEQ ID Ns 18, ó SEQ ID Ns 10, y una región constante en donde la secuencia de aminoácidos está representada por SEQ ID Ns 12, para dicho receptor, preferentemente inferior a 10-7M, especialmente inferior a 10-8M, en particular comprendido entre 10-9M y 10-11M.
ARP110101115A 2010-05-12 2011-04-01 Anticuerpos humanizados 12g4 mutados y sus fragmentos dirigidos contra el receptor humano de la hormona anti-mulleriana de tipo ii AR081159A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1053712A FR2959994B1 (fr) 2010-05-12 2010-05-12 Nouveaux anticorps humanises 12g4 mutes et leurs fragments diriges contre le recepteur humain de l'hormone anti-mullerienne de type ii

Publications (1)

Publication Number Publication Date
AR081159A1 true AR081159A1 (es) 2012-07-04

Family

ID=43413855

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110101115A AR081159A1 (es) 2010-05-12 2011-04-01 Anticuerpos humanizados 12g4 mutados y sus fragmentos dirigidos contra el receptor humano de la hormona anti-mulleriana de tipo ii

Country Status (11)

Country Link
US (2) US9012607B2 (es)
EP (1) EP2569333B1 (es)
JP (2) JP6043998B2 (es)
CN (1) CN103119059B (es)
AR (1) AR081159A1 (es)
BR (1) BR112012028859B1 (es)
CA (1) CA2798336C (es)
DK (1) DK2569333T3 (es)
ES (1) ES2661080T3 (es)
FR (1) FR2959994B1 (es)
WO (1) WO2011141653A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103718218B (zh) * 2011-07-26 2016-10-05 美国联合包裹服务公司 用于管理故障代码的系统和方法
FR2984750B1 (fr) 2011-12-23 2014-01-10 Lfb Biotechnologies Nouvelles compositions pharmaceutiques comprenant un anticorps liant le recepteur humain de l'hormone anti-mullerienne de type ii
WO2017025458A1 (en) * 2015-08-07 2017-02-16 Gamamabs Pharma Antibodies, antibody drug conjugates and methods of use
WO2017079303A1 (en) * 2015-11-02 2017-05-11 The Cleveland Clinic Foundation Sequentially orchestrated immune checkpoint therapy for the treatment and prevention of cancer
FR3060394B1 (fr) 2016-12-16 2019-05-24 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Combinaison d'anticorps anti-cd303 et anti-amhrii
MX2019012136A (es) 2017-04-14 2020-07-20 Gamamabs Pharma Compuestos de union al receptor de la hormona antimulleriana tipo ii (amhrii) para prevenir o tratar canceres de pulmon.
WO2018189379A1 (en) 2017-04-14 2018-10-18 Gamamabs Pharma Amhrii-binding compounds for preventing or treating cancers
CA3064333A1 (en) * 2017-05-29 2018-12-06 Gamamabs Pharma Cancer-associated immunosuppression inhibitor
EP3789401A1 (en) 2019-09-03 2021-03-10 Gamamabs Pharma Amhrii-binding antibody drug conjugates and their use thereof in the treatment of cancers
EP3812008A1 (en) 2019-10-23 2021-04-28 Gamamabs Pharma Amh-competitive antagonist antibody

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002049672A2 (en) * 2000-12-21 2002-06-27 Mcgill University Conjugates of antibodies and anticancer drugs
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US7217797B2 (en) * 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2005005615A2 (en) * 2003-07-08 2005-01-20 Fox Chase Cancer Center Anti-mullerian inhibiting substance type ii receptor (misiir) immunoconjugates to detect and treat cancer
CA2631327C (en) * 2005-12-02 2015-10-13 Genentech, Inc. Her2 binding polypeptides and uses thereof
JP5524610B2 (ja) * 2006-04-07 2014-06-18 ザ リサーチ ファウンデーション オブ ステイト ユニバーシティー オブ ニューヨーク トランスコバラミン受容体ポリペプチド、核酸およびその調節因子、ならびに細胞の増殖の調節ならびにガンおよびコバラミン欠損症の処置に使用する関連方法
CN101506358B (zh) * 2006-05-15 2013-07-17 免疫医学股份有限公司 使用偶合的抗体或抗体片段治疗人免疫缺陷病毒感染的方法和组合物
EP1918304A1 (en) * 2006-11-02 2008-05-07 Institut National De La Sante Et De La Recherche Medicale (Inserm) Monoclonal antibodies against the human anti-müllerian hormone type II receptor (AMHR-II)

Also Published As

Publication number Publication date
WO2011141653A1 (fr) 2011-11-17
CA2798336A1 (fr) 2011-11-17
EP2569333A1 (fr) 2013-03-20
BR112012028859A8 (pt) 2017-12-05
US20130136743A1 (en) 2013-05-30
CN103119059B (zh) 2016-06-29
EP2569333B1 (fr) 2017-12-13
BR112012028859A2 (es) 2017-08-15
DK2569333T3 (en) 2018-03-26
CN103119059A (zh) 2013-05-22
FR2959994B1 (fr) 2012-08-24
BR112012028859B1 (pt) 2022-02-22
JP6435295B2 (ja) 2018-12-05
FR2959994A1 (fr) 2011-11-18
CA2798336C (fr) 2018-08-21
US9012607B2 (en) 2015-04-21
JP2013534408A (ja) 2013-09-05
JP6043998B2 (ja) 2016-12-14
US20150232563A1 (en) 2015-08-20
ES2661080T3 (es) 2018-03-27
JP2017029139A (ja) 2017-02-09
US9637544B2 (en) 2017-05-02

Similar Documents

Publication Publication Date Title
AR081159A1 (es) Anticuerpos humanizados 12g4 mutados y sus fragmentos dirigidos contra el receptor humano de la hormona anti-mulleriana de tipo ii
MX2021013336A (es) Anticuerpos y receptores de antigeno quimericos especificos para cd19.
AR127371A2 (es) Receptores quiméricos de flt3 y métodos para usarlos
MX2021005022A (es) Receptores de antigenos quimericos especificos para el miembro d del grupo 5 de la clase c del receptor acoplado a proteina g (gprc5d).
AR085591A1 (es) Anticuerpos del antigeno carcinoembrionario humano (cea)
HRP20201090T1 (hr) Protutijela anti-icos
WO2014011988A3 (en) Enhancing activity of car t cells by co-introducing a bispecific antibody
PE20220495A1 (es) Receptores antigenicos quimericos y agentes de union dirigidos a dll3
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
PE20110225A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5
MX2021009151A (es) Anticuerpos y receptores de antigeno quimerico especificos para ror1.
AR102239A1 (es) Anticuerpos anti-ox40 humanizados y sus usos
MX2019001184A (es) Anticuerpos anti-idiotípicos y métodos relacionados.
AR096617A1 (es) Anticuerpos anti-tweakr y sus usos
EA201790624A1 (ru) Нацеливание цитотоксических клеток с химерными рецепторами для адоптивной иммунотерапии
AR085383A1 (es) Anticuerpos contra el il33r humano y usos de los mismos
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
AR077973A1 (es) Anticuerpos anti-cdcp1 humanizados
RU2014108208A (ru) Мыши с гуманизированной универсальной легкой цепью
PE20180249A1 (es) Anticuerpos neutralizadores anti-ccl20
PE20120899A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b
PE20141908A1 (es) Anticuerpos cd47 y metodos de uso los mismos
PE20121649A1 (es) Anticuerpos monoclonales frente a progastrina y sus usos
ES2658224T3 (es) Anticuerpos humanizados contra receptores de tipo Toll 2 y sus usos
CL2011002039A1 (es) Anticuerpo humanizado que se une al cd19 humano; acido nucleico aislado que codifica dicho anticuerpo; vector y celula huesped; composicion e inmunoconjugado; metodo para inhibir el crecimiento de celulas de tumor que expresan cd19.

Legal Events

Date Code Title Description
FG Grant, registration